Cargando…

Endothelial dysfunction and low-grade inflammation in the transition to renal replacement therapy

INTRODUCTION: End-stage renal disease (ESRD) strongly associates with cardiovascular disease (CVD) risk. This risk is not completely mitigated by renal replacement therapy. Endothelial dysfunction (ED) and low-grade inflammation (LGI) may contribute to the increased CVD risk. However, data on serum...

Descripción completa

Detalles Bibliográficos
Autores principales: van Gennip, April C. E., Broers, Natascha J. H., ter Meulen, Karlien J., Canaud, Bernard, Christiaans, Maarten H. L., Cornelis, Tom, Gelens, Mariëlle A. C. J., Hermans, Marc M. H., Konings, Constantijn J. A. M., van der Net, Jeroen B., van der Sande, Frank M., Schalkwijk, Casper G., Stifft, Frank, Wirtz, Joris J. J. M., Kooman, Jeroen P., Martens, Remy J. H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6743867/
https://www.ncbi.nlm.nih.gov/pubmed/31518378
http://dx.doi.org/10.1371/journal.pone.0222547
_version_ 1783451339515232256
author van Gennip, April C. E.
Broers, Natascha J. H.
ter Meulen, Karlien J.
Canaud, Bernard
Christiaans, Maarten H. L.
Cornelis, Tom
Gelens, Mariëlle A. C. J.
Hermans, Marc M. H.
Konings, Constantijn J. A. M.
van der Net, Jeroen B.
van der Sande, Frank M.
Schalkwijk, Casper G.
Stifft, Frank
Wirtz, Joris J. J. M.
Kooman, Jeroen P.
Martens, Remy J. H.
author_facet van Gennip, April C. E.
Broers, Natascha J. H.
ter Meulen, Karlien J.
Canaud, Bernard
Christiaans, Maarten H. L.
Cornelis, Tom
Gelens, Mariëlle A. C. J.
Hermans, Marc M. H.
Konings, Constantijn J. A. M.
van der Net, Jeroen B.
van der Sande, Frank M.
Schalkwijk, Casper G.
Stifft, Frank
Wirtz, Joris J. J. M.
Kooman, Jeroen P.
Martens, Remy J. H.
author_sort van Gennip, April C. E.
collection PubMed
description INTRODUCTION: End-stage renal disease (ESRD) strongly associates with cardiovascular disease (CVD) risk. This risk is not completely mitigated by renal replacement therapy. Endothelial dysfunction (ED) and low-grade inflammation (LGI) may contribute to the increased CVD risk. However, data on serum biomarkers of ED and LGI during the transition to renal replacement therapy (dialysis and kidney transplantation) are scarce. METHODS: We compared serum biomarkers of ED and LGI between 36 controls, 43 participants with chronic kidney disease (CKD) stage 5 non-dialysis (CKD5-ND), 20 participants with CKD stage 5 hemodialysis (CKD5-HD) and 14 participants with CKD stage 5 peritoneal dialysis (CKD5-PD). Further, in 34 and 15 participants repeated measurements were available during the first six months following dialysis initiation and kidney transplantation, respectively. Serum biomarkers of ED (sVCAM-1, E-selectin, P-selectin, thrombomodulin, sICAM-1, sICAM-3) and LGI (hs-CRP, SAA, IL-6, IL-8, TNF-α) were measured with a single- or multiplex array detection system based on electro-chemiluminescence technology. RESULTS: In linear regression analyses adjusted for potential confounders, participants with ESRD had higher levels of most serum biomarkers of ED and LGI than controls. In addition, in CKD5-HD levels of serum biomarkers of ED and LGI were largely similar to those in CKD5-ND. In contrast, in CKD5-PD levels of biomarkers of ED were higher than in CKD5-ND and CKD5-HD. Similarly, in linear mixed model analyses sVCAM-1, thrombomodulin, sICAM-1 and sICAM-3 increased after PD initiation. In contrast, incident HD patients showed an increase in sVCAM-1, P-selectin and TNF-α, but a decline of hs-CRP, SAA and IL-6. Further, following kidney transplantation sVCAM-1, thrombomodulin, sICAM-3 and TNF-α were lower at three months post-transplantation and remained stable in the three months thereafter. CONCLUSIONS: Levels of serum biomarkers of ED and LGI were higher in ESRD as compared with controls. In addition, PD initiation and, less convincingly, HD initiation may increase levels of selected serum biomarkers of ED and LGI on top of uremia per se. In contrast to dialysis, several serum biomarkers of ED and LGI markedly declined following kidney transplantation.
format Online
Article
Text
id pubmed-6743867
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-67438672019-09-20 Endothelial dysfunction and low-grade inflammation in the transition to renal replacement therapy van Gennip, April C. E. Broers, Natascha J. H. ter Meulen, Karlien J. Canaud, Bernard Christiaans, Maarten H. L. Cornelis, Tom Gelens, Mariëlle A. C. J. Hermans, Marc M. H. Konings, Constantijn J. A. M. van der Net, Jeroen B. van der Sande, Frank M. Schalkwijk, Casper G. Stifft, Frank Wirtz, Joris J. J. M. Kooman, Jeroen P. Martens, Remy J. H. PLoS One Research Article INTRODUCTION: End-stage renal disease (ESRD) strongly associates with cardiovascular disease (CVD) risk. This risk is not completely mitigated by renal replacement therapy. Endothelial dysfunction (ED) and low-grade inflammation (LGI) may contribute to the increased CVD risk. However, data on serum biomarkers of ED and LGI during the transition to renal replacement therapy (dialysis and kidney transplantation) are scarce. METHODS: We compared serum biomarkers of ED and LGI between 36 controls, 43 participants with chronic kidney disease (CKD) stage 5 non-dialysis (CKD5-ND), 20 participants with CKD stage 5 hemodialysis (CKD5-HD) and 14 participants with CKD stage 5 peritoneal dialysis (CKD5-PD). Further, in 34 and 15 participants repeated measurements were available during the first six months following dialysis initiation and kidney transplantation, respectively. Serum biomarkers of ED (sVCAM-1, E-selectin, P-selectin, thrombomodulin, sICAM-1, sICAM-3) and LGI (hs-CRP, SAA, IL-6, IL-8, TNF-α) were measured with a single- or multiplex array detection system based on electro-chemiluminescence technology. RESULTS: In linear regression analyses adjusted for potential confounders, participants with ESRD had higher levels of most serum biomarkers of ED and LGI than controls. In addition, in CKD5-HD levels of serum biomarkers of ED and LGI were largely similar to those in CKD5-ND. In contrast, in CKD5-PD levels of biomarkers of ED were higher than in CKD5-ND and CKD5-HD. Similarly, in linear mixed model analyses sVCAM-1, thrombomodulin, sICAM-1 and sICAM-3 increased after PD initiation. In contrast, incident HD patients showed an increase in sVCAM-1, P-selectin and TNF-α, but a decline of hs-CRP, SAA and IL-6. Further, following kidney transplantation sVCAM-1, thrombomodulin, sICAM-3 and TNF-α were lower at three months post-transplantation and remained stable in the three months thereafter. CONCLUSIONS: Levels of serum biomarkers of ED and LGI were higher in ESRD as compared with controls. In addition, PD initiation and, less convincingly, HD initiation may increase levels of selected serum biomarkers of ED and LGI on top of uremia per se. In contrast to dialysis, several serum biomarkers of ED and LGI markedly declined following kidney transplantation. Public Library of Science 2019-09-13 /pmc/articles/PMC6743867/ /pubmed/31518378 http://dx.doi.org/10.1371/journal.pone.0222547 Text en © 2019 Gennip et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
van Gennip, April C. E.
Broers, Natascha J. H.
ter Meulen, Karlien J.
Canaud, Bernard
Christiaans, Maarten H. L.
Cornelis, Tom
Gelens, Mariëlle A. C. J.
Hermans, Marc M. H.
Konings, Constantijn J. A. M.
van der Net, Jeroen B.
van der Sande, Frank M.
Schalkwijk, Casper G.
Stifft, Frank
Wirtz, Joris J. J. M.
Kooman, Jeroen P.
Martens, Remy J. H.
Endothelial dysfunction and low-grade inflammation in the transition to renal replacement therapy
title Endothelial dysfunction and low-grade inflammation in the transition to renal replacement therapy
title_full Endothelial dysfunction and low-grade inflammation in the transition to renal replacement therapy
title_fullStr Endothelial dysfunction and low-grade inflammation in the transition to renal replacement therapy
title_full_unstemmed Endothelial dysfunction and low-grade inflammation in the transition to renal replacement therapy
title_short Endothelial dysfunction and low-grade inflammation in the transition to renal replacement therapy
title_sort endothelial dysfunction and low-grade inflammation in the transition to renal replacement therapy
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6743867/
https://www.ncbi.nlm.nih.gov/pubmed/31518378
http://dx.doi.org/10.1371/journal.pone.0222547
work_keys_str_mv AT vangennipaprilce endothelialdysfunctionandlowgradeinflammationinthetransitiontorenalreplacementtherapy
AT broersnataschajh endothelialdysfunctionandlowgradeinflammationinthetransitiontorenalreplacementtherapy
AT termeulenkarlienj endothelialdysfunctionandlowgradeinflammationinthetransitiontorenalreplacementtherapy
AT canaudbernard endothelialdysfunctionandlowgradeinflammationinthetransitiontorenalreplacementtherapy
AT christiaansmaartenhl endothelialdysfunctionandlowgradeinflammationinthetransitiontorenalreplacementtherapy
AT cornelistom endothelialdysfunctionandlowgradeinflammationinthetransitiontorenalreplacementtherapy
AT gelensmarielleacj endothelialdysfunctionandlowgradeinflammationinthetransitiontorenalreplacementtherapy
AT hermansmarcmh endothelialdysfunctionandlowgradeinflammationinthetransitiontorenalreplacementtherapy
AT koningsconstantijnjam endothelialdysfunctionandlowgradeinflammationinthetransitiontorenalreplacementtherapy
AT vandernetjeroenb endothelialdysfunctionandlowgradeinflammationinthetransitiontorenalreplacementtherapy
AT vandersandefrankm endothelialdysfunctionandlowgradeinflammationinthetransitiontorenalreplacementtherapy
AT schalkwijkcasperg endothelialdysfunctionandlowgradeinflammationinthetransitiontorenalreplacementtherapy
AT stifftfrank endothelialdysfunctionandlowgradeinflammationinthetransitiontorenalreplacementtherapy
AT wirtzjorisjjm endothelialdysfunctionandlowgradeinflammationinthetransitiontorenalreplacementtherapy
AT koomanjeroenp endothelialdysfunctionandlowgradeinflammationinthetransitiontorenalreplacementtherapy
AT martensremyjh endothelialdysfunctionandlowgradeinflammationinthetransitiontorenalreplacementtherapy